Telix Pharmaceuticals (NASDAQ:TLX) Given “Outperform” Rating at Wedbush

Telix Pharmaceuticals (NASDAQ:TLX)‘s stock had its “outperform” rating reiterated by equities research analysts at Wedbush in a report released on Wednesday, Benzinga reports. They presently have a $22.00 target price on the stock. Wedbush’s price objective indicates a potential upside of 94.00% from the company’s previous close.

A number of other equities analysts have also commented on TLX. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a research report on Tuesday, September 15th. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, September 21st. Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Finally, Weiss Ratings raised shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $20.50.

Telix Pharmaceuticals Price Performance

NASDAQ:TLX traded down $0.28 during mid-day trading on Wednesday, reaching $11.34. 427,611 shares of the company’s stock were exchanged, compared to its average volume of 226,455. Telix Pharmaceuticals has a one year low of $6.28 and a one year high of $13.11. The business’s fifty day simple moving average is $11.37 and its two-hundred day simple moving average is $10.52. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several hedge funds have recently bought and sold shares of TLX. Hennion & Walsh Asset Management Inc. bought a new position in Telix Pharmaceuticals in the 2nd quarter valued at about $1,731,000. Private Advisor Group LLC grew its holdings in shares of Telix Pharmaceuticals by 276.3% during the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after purchasing an additional 128,070 shares during the last quarter. XY Capital Ltd grew its holdings in shares of Telix Pharmaceuticals by 468.0% during the 2nd quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock valued at $822,000 after purchasing an additional 58,739 shares during the last quarter. Lazard Asset Management LLC grew its holdings in shares of Telix Pharmaceuticals by 15.7% during the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after purchasing an additional 39,400 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after purchasing an additional 8,423 shares during the last quarter.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.